Report Detail
Global Immune Thrombocytopenia Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030
- RnM4597654 |
- 02 July, 2024 |
- Global |
- 103 Pages |
- GIR (Global Info Research) |
- Other
According to our (Global Info Research) latest study, the global Immune Thrombocytopenia Treatment market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Immune thrombocytopenia (ITP) is a bleeding disorder caused by thrombocytopenia not associated with a systemic disease. Typically, it is chronic in adults, but it is usually acute and self-limited in children. Spleen size is normal in the absence of another underlying condition.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Immune Thrombocytopenia Treatment industry chain, the market status of Hospitals and Clinics (Corticosteroids, Intravenous Immunoglobulin (IVIG)), Research and Academic Institutes (Corticosteroids, Intravenous Immunoglobulin (IVIG)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Immune Thrombocytopenia Treatment.
Regionally, the report analyzes the Immune Thrombocytopenia Treatment markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Immune Thrombocytopenia Treatment market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Immune Thrombocytopenia Treatment market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Immune Thrombocytopenia Treatment industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Corticosteroids, Intravenous Immunoglobulin (IVIG)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Immune Thrombocytopenia Treatment market.
Regional Analysis: The report involves examining the Immune Thrombocytopenia Treatment market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Immune Thrombocytopenia Treatment market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Immune Thrombocytopenia Treatment:
Company Analysis: Report covers individual Immune Thrombocytopenia Treatment players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Immune Thrombocytopenia Treatment This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals and Clinics, Research and Academic Institutes).
Technology Analysis: Report covers specific technologies relevant to Immune Thrombocytopenia Treatment. It assesses the current state, advancements, and potential future developments in Immune Thrombocytopenia Treatment areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Immune Thrombocytopenia Treatment market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Immune Thrombocytopenia Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Corticosteroids
Intravenous Immunoglobulin (IVIG)
Anti-D Immunoglobulin
Thrombopoietin Receptor Agonist (TPO-RA)
Others
Market segment by Application
Hospitals and Clinics
Research and Academic Institutes
Others
Market segment by players, this report covers
CSL Behring
Amgen
F.Hoffmann-La Roche
Kyowa Hakko Kirin
Rigel Pharmaceuticals
Shionogi
Dova Pharmaceuticals
Novartis
Shire
Ligand Pharmaceuticals
GSK
Grifols Biologicals
Jiangsu Hengrui Pharmaceutical
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Immune Thrombocytopenia Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Immune Thrombocytopenia Treatment, with revenue, gross margin and global market share of Immune Thrombocytopenia Treatment from 2019 to 2024.
Chapter 3, the Immune Thrombocytopenia Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Immune Thrombocytopenia Treatment market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Immune Thrombocytopenia Treatment.
Chapter 13, to describe Immune Thrombocytopenia Treatment research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope of Immune Thrombocytopenia Treatment
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Immune Thrombocytopenia Treatment by Type
- 1.3.1 Overview: Global Immune Thrombocytopenia Treatment Market Size by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Global Immune Thrombocytopenia Treatment Consumption Value Market Share by Type in 2023
- 1.3.3 Corticosteroids
- 1.3.4 Intravenous Immunoglobulin (IVIG)
- 1.3.5 Anti-D Immunoglobulin
- 1.3.6 Thrombopoietin Receptor Agonist (TPO-RA)
- 1.3.7 Others
- 1.4 Global Immune Thrombocytopenia Treatment Market by Application
- 1.4.1 Overview: Global Immune Thrombocytopenia Treatment Market Size by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Hospitals and Clinics
- 1.4.3 Research and Academic Institutes
- 1.4.4 Others
- 1.5 Global Immune Thrombocytopenia Treatment Market Size & Forecast
- 1.6 Global Immune Thrombocytopenia Treatment Market Size and Forecast by Region
- 1.6.1 Global Immune Thrombocytopenia Treatment Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global Immune Thrombocytopenia Treatment Market Size by Region, (2019-2030)
- 1.6.3 North America Immune Thrombocytopenia Treatment Market Size and Prospect (2019-2030)
- 1.6.4 Europe Immune Thrombocytopenia Treatment Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific Immune Thrombocytopenia Treatment Market Size and Prospect (2019-2030)
- 1.6.6 South America Immune Thrombocytopenia Treatment Market Size and Prospect (2019-2030)
- 1.6.7 Middle East and Africa Immune Thrombocytopenia Treatment Market Size and Prospect (2019-2030)
2 Company Profiles
- 2.1 CSL Behring
- 2.1.1 CSL Behring Details
- 2.1.2 CSL Behring Major Business
- 2.1.3 CSL Behring Immune Thrombocytopenia Treatment Product and Solutions
- 2.1.4 CSL Behring Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 CSL Behring Recent Developments and Future Plans
- 2.2 Amgen
- 2.2.1 Amgen Details
- 2.2.2 Amgen Major Business
- 2.2.3 Amgen Immune Thrombocytopenia Treatment Product and Solutions
- 2.2.4 Amgen Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Amgen Recent Developments and Future Plans
- 2.3 F.Hoffmann-La Roche
- 2.3.1 F.Hoffmann-La Roche Details
- 2.3.2 F.Hoffmann-La Roche Major Business
- 2.3.3 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Product and Solutions
- 2.3.4 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 F.Hoffmann-La Roche Recent Developments and Future Plans
- 2.4 Kyowa Hakko Kirin
- 2.4.1 Kyowa Hakko Kirin Details
- 2.4.2 Kyowa Hakko Kirin Major Business
- 2.4.3 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Product and Solutions
- 2.4.4 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Kyowa Hakko Kirin Recent Developments and Future Plans
- 2.5 Rigel Pharmaceuticals
- 2.5.1 Rigel Pharmaceuticals Details
- 2.5.2 Rigel Pharmaceuticals Major Business
- 2.5.3 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Product and Solutions
- 2.5.4 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Rigel Pharmaceuticals Recent Developments and Future Plans
- 2.6 Shionogi
- 2.6.1 Shionogi Details
- 2.6.2 Shionogi Major Business
- 2.6.3 Shionogi Immune Thrombocytopenia Treatment Product and Solutions
- 2.6.4 Shionogi Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Shionogi Recent Developments and Future Plans
- 2.7 Dova Pharmaceuticals
- 2.7.1 Dova Pharmaceuticals Details
- 2.7.2 Dova Pharmaceuticals Major Business
- 2.7.3 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Product and Solutions
- 2.7.4 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Dova Pharmaceuticals Recent Developments and Future Plans
- 2.8 Novartis
- 2.8.1 Novartis Details
- 2.8.2 Novartis Major Business
- 2.8.3 Novartis Immune Thrombocytopenia Treatment Product and Solutions
- 2.8.4 Novartis Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Novartis Recent Developments and Future Plans
- 2.9 Shire
- 2.9.1 Shire Details
- 2.9.2 Shire Major Business
- 2.9.3 Shire Immune Thrombocytopenia Treatment Product and Solutions
- 2.9.4 Shire Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.9.5 Shire Recent Developments and Future Plans
- 2.10 Ligand Pharmaceuticals
- 2.10.1 Ligand Pharmaceuticals Details
- 2.10.2 Ligand Pharmaceuticals Major Business
- 2.10.3 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Product and Solutions
- 2.10.4 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Ligand Pharmaceuticals Recent Developments and Future Plans
- 2.11 GSK
- 2.11.1 GSK Details
- 2.11.2 GSK Major Business
- 2.11.3 GSK Immune Thrombocytopenia Treatment Product and Solutions
- 2.11.4 GSK Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.11.5 GSK Recent Developments and Future Plans
- 2.12 Grifols Biologicals
- 2.12.1 Grifols Biologicals Details
- 2.12.2 Grifols Biologicals Major Business
- 2.12.3 Grifols Biologicals Immune Thrombocytopenia Treatment Product and Solutions
- 2.12.4 Grifols Biologicals Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.12.5 Grifols Biologicals Recent Developments and Future Plans
- 2.13 Jiangsu Hengrui Pharmaceutical
- 2.13.1 Jiangsu Hengrui Pharmaceutical Details
- 2.13.2 Jiangsu Hengrui Pharmaceutical Major Business
- 2.13.3 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Product and Solutions
- 2.13.4 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Revenue, Gross Margin and Market Share (2019-2024)
- 2.13.5 Jiangsu Hengrui Pharmaceutical Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Immune Thrombocytopenia Treatment Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of Immune Thrombocytopenia Treatment by Company Revenue
- 3.2.2 Top 3 Immune Thrombocytopenia Treatment Players Market Share in 2023
- 3.2.3 Top 6 Immune Thrombocytopenia Treatment Players Market Share in 2023
- 3.3 Immune Thrombocytopenia Treatment Market: Overall Company Footprint Analysis
- 3.3.1 Immune Thrombocytopenia Treatment Market: Region Footprint
- 3.3.2 Immune Thrombocytopenia Treatment Market: Company Product Type Footprint
- 3.3.3 Immune Thrombocytopenia Treatment Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Immune Thrombocytopenia Treatment Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global Immune Thrombocytopenia Treatment Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
- 5.1 Global Immune Thrombocytopenia Treatment Consumption Value Market Share by Application (2019-2024)
- 5.2 Global Immune Thrombocytopenia Treatment Market Forecast by Application (2025-2030)
6 North America
- 6.1 North America Immune Thrombocytopenia Treatment Consumption Value by Type (2019-2030)
- 6.2 North America Immune Thrombocytopenia Treatment Consumption Value by Application (2019-2030)
- 6.3 North America Immune Thrombocytopenia Treatment Market Size by Country
- 6.3.1 North America Immune Thrombocytopenia Treatment Consumption Value by Country (2019-2030)
- 6.3.2 United States Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 6.3.3 Canada Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 6.3.4 Mexico Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
7 Europe
- 7.1 Europe Immune Thrombocytopenia Treatment Consumption Value by Type (2019-2030)
- 7.2 Europe Immune Thrombocytopenia Treatment Consumption Value by Application (2019-2030)
- 7.3 Europe Immune Thrombocytopenia Treatment Market Size by Country
- 7.3.1 Europe Immune Thrombocytopenia Treatment Consumption Value by Country (2019-2030)
- 7.3.2 Germany Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 7.3.3 France Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 7.3.5 Russia Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 7.3.6 Italy Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
8 Asia-Pacific
- 8.1 Asia-Pacific Immune Thrombocytopenia Treatment Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific Immune Thrombocytopenia Treatment Consumption Value by Application (2019-2030)
- 8.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region
- 8.3.1 Asia-Pacific Immune Thrombocytopenia Treatment Consumption Value by Region (2019-2030)
- 8.3.2 China Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 8.3.3 Japan Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 8.3.4 South Korea Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 8.3.5 India Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 8.3.7 Australia Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
9 South America
- 9.1 South America Immune Thrombocytopenia Treatment Consumption Value by Type (2019-2030)
- 9.2 South America Immune Thrombocytopenia Treatment Consumption Value by Application (2019-2030)
- 9.3 South America Immune Thrombocytopenia Treatment Market Size by Country
- 9.3.1 South America Immune Thrombocytopenia Treatment Consumption Value by Country (2019-2030)
- 9.3.2 Brazil Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 9.3.3 Argentina Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
10 Middle East & Africa
- 10.1 Middle East & Africa Immune Thrombocytopenia Treatment Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa Immune Thrombocytopenia Treatment Consumption Value by Application (2019-2030)
- 10.3 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country
- 10.3.1 Middle East & Africa Immune Thrombocytopenia Treatment Consumption Value by Country (2019-2030)
- 10.3.2 Turkey Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
- 10.3.4 UAE Immune Thrombocytopenia Treatment Market Size and Forecast (2019-2030)
11 Market Dynamics
- 11.1 Immune Thrombocytopenia Treatment Market Drivers
- 11.2 Immune Thrombocytopenia Treatment Market Restraints
- 11.3 Immune Thrombocytopenia Treatment Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Immune Thrombocytopenia Treatment Industry Chain
- 12.2 Immune Thrombocytopenia Treatment Upstream Analysis
- 12.3 Immune Thrombocytopenia Treatment Midstream Analysis
- 12.4 Immune Thrombocytopenia Treatment Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Immune Thrombocytopenia Treatment. Industry analysis & Market Report on Immune Thrombocytopenia Treatment is a syndicated market report, published as Global Immune Thrombocytopenia Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Immune Thrombocytopenia Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
